Correspondence  |   April 2013
In Reply:
Author Affiliations & Notes
  • Klaus Görlinger, Dr. med.
    University Hospital Essen, University Duisburg-Essen, Hufelandstrasse, Germany.
  • (Accepted for publication December 19, 2012.)
    (Accepted for publication December 19, 2012.)×
Article Information
Correspondence   |   April 2013
In Reply:
Anesthesiology 04 2013, Vol.118, 988-990. doi:10.1097/ALN.0b013e318286fb63
Anesthesiology 04 2013, Vol.118, 988-990. doi:10.1097/ALN.0b013e318286fb63
We appreciate Dr. Ziemann-Gimmel’s commendation of our randomized clinical trial (RCT) on efficacy of point-of-care (POC) testing in coagulopathic cardiac surgery patients and are happy to comment on his two important considerations.1 
We agree that increased intraoperative blood loss and subsequent retransfusion of salvaged washed erythrocytes can result in dilutional coagulopathy and, therefore, may further increase transfusion requirements. In addition, transfusion of fresh frozen plasma in order to treat or avoid dilutional coagulopathy results in dilution of erythrocytes and platelets and may increase transfusion requirements for erythrocytes and platelets, too. The only way to avoid this vicious circle is to stop bleeding as quickly as possible. We thank Dr. Ziemann-Gimmel for pointing out that POC testing-guided hemostatic therapy in our RCT not only reduced postoperative chest tube blood loss by 33%, but also reduced intraoperative retransfused salvaged washed erythrocytes by about 50%, reflecting a significant reduction in intraoperative blood loss. As in our study cell salvage was not used before weaning from cardiopulmonary bypass and heparin-reversal by protamine, this demonstrates again that our POC-guided hemostatic therapy was superior to the conventional algorithm. These results are in line with our retrospective cohort study in 3,865 cardiac surgical patients showing a significant reduction in intraoperative erythrocyte and fresh frozen plasma transfusion requirements after implementation of a coagulation management algorithm based on POC testing and first-line therapy with specific coagulation factor concentrates.2  Accordingly, both studies demonstrated a significant reduction in the incidence of massive transfusion by 88% and 50%, respectively.1,2 
In regard to the second comment of Dr. Ziemann-Gimmel, we have to point out that in our prospective RCT the patients were randomly assigned to the conventional or POC group after heparin reversal following cardiopulmonary bypass, as clearly described in the methods section on page 532. Therefore, the first part of the POC algorithm presented in figure 1C (Multiplate [Roche Diagnostics GmbH, Mannheim, Germany]® testing in patients on clopidogrel at the beginning of surgery and ROTEM [Tem International GmbH, Munich, Germany]® analysis after declamping of the aorta) has not been used in this RCT. We agree that presenting the whole POC algorithm primarily used in our retrospective cohort study2  is capable of being misunderstood by the reader even if the entrance point into the POC algorithm was clearly defined in the methods section. Therefore, we straighten again that neither POC testing nor hemostatic interventions have been performed before detection of diffuse bleeding after heparin reversal by protamine and randomization of the patients. Therefore, costs of unnecessary testing or hemostatic therapy have not been considered in this RCT. However, the comment of Dr. Ziemann-Gimmel that POC testing was applied to all cardiac patients in our retrospective cohort study2  is not correct. As clearly pointed out in the methods (page 1183) and results sections (page 1184) of this study, POC testing and hemostatic therapy were done solely in patients at high risk of bleeding or with clinically relevant diffuse bleeding after heparin reversal with protamine. In this cohort study, thromboelastometry was performed in approximately 17.5% and impedance aggregometry in 10.6% of the study population after implementation of the POC algorithm.2  This was done because we wanted to restrict POC testing and hemostatic therapy to bleeding patients, solely, and to avoid treating numbers. Therefore, we completely agree with Dr. Ziemann-Gimmel’s comment that reduction in transfusion requirements and cost savings can be assumed to be substantially less in an institution with a low rate of high-risk complex cardiac surgery or low baseline transfusion requirements. This has already been shown by Avidan et al.,3  and accordingly, we performed our RCT in a highly selected patient population undergoing complex cardiac surgery with diffuse bleeding after heparin reversal.
We thank Drs. Colombo and Ghori for their kind comment on our straight and precise study design and the clear results in regard to the primary endpoint (number of transfused units of packed erythrocytes) of our RCT.1 
We agree that the intraoperative inclusion criterion “diffuse bleeding from capillary beds at wound surface requiring hemostatic therapy” after heparin reversal with protamine is highly dependent on the personal assessment. However, this inclusion criterion has just been used in order to exclude nonbleeding patients from our RCT before randomization. Therefore, it is unlikely that this inclusion criterion may have resulted in any differences between both study groups. As it was not possible to use the same inclusion criterion after closing the chest and transferring the patient to the intensive care unit, we chose the second criterion “blood loss exceeding 250 ml/h or 50 ml/10 min” for postoperative inclusion of patients. By the way, the aim of our RCT was not to predict bleeding but to stop bleeding as quickly and effectively as possible.
We also agree that reporting on the primary endpoint of a study is most important. However, it seems not reasonable for us to waive on reporting on predefined secondary endpoints. Furthermore, the secondary endpoints number of transfused units of fresh frozen plasma, intraoperative retransfused salvaged washed erythrocytes, postoperative chest tube blood loss, time of mechanical ventilation, and incidence of composite adverse events were not only close to statistical significance (as stated by Dr. Colombo and Ghori), but also showed highly significant difference between both study groups (P < 0.001).1  Furthermore, we disagree that publishing the Kaplan–Meier curve is misleading. We are aware of the fact that the reported survival rate in the conventional group of our RCT is different from that in other studies cited by Colombo and Ghori.2,4  However, this can be explained by the highly selective patient population in our RCT, including patients undergoing complex cardiac surgery and suffering from diffuse bleeding after heparin reversal, solely. Obviously, this group of highly selected patients suffering from microvascular bleeding after complex cardiac surgery present a higher mortality compared to observational studies including all kind of cardiovascular surgery.2,4  Notably, the 6-month mortality in the conventional group of our RCT (20%) is very close to the 30-day mortality in cardiac surgical patients with postoperative hemorrhage reported by Christensen and von Heymann (22.4%), whereas the mortality in our POC group (4%) corresponds well to the mortality in the nonhemorrhage group (5.5%) of the study published by Christensen and von Heymann.5  This supports the hypothesis that early POC-guided hemostatic therapy improves patient outcome by avoiding massive transfusion and subsequent transfusion-associated adverse events. However, we pointed out in our publication several times that this RCT was not powered for mortality and a multicenter study with a larger study population is needed to confirm the results of our single-center RCT.
Klaus Görlinger, Dr. med.,* Christian Friedrich Weber, Dr. med., Kai Zacharowski, Prof. Dr. med., Ph.D., F.R.C.A. *University Hospital Essen, University Duisburg-Essen, Hufelandstrasse, Germany.
Weber, CF, Görlinger, K, Meininger, D, Herrmann, E, Bingold, T, Moritz, A, Cohn, LH, Zacharowski, K Point-of-care testing: A prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients.. Anesthesiology. (2012). 117 531–47 [Article] [PubMed]
Görlinger, K, Dirkmann, D, Hanke, AA, Kamler, M, Kottenberg, E, Thielmann, M, Jakob, H, Peters, J First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: A retrospective, single-center cohort study.. Anesthesiology. (2011). 115 1179–91 [PubMed]
Avidan, MS, Alcock, EL, Da Fonseca, J, Ponte, J, Desai, JB, Despotis, GJ, Hunt, BJ Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery.. Br J Anaesth. (2004). 92 178–86 [Article] [PubMed]
Murphy, GJ, Reeves, BC, Rogers, CA, Rizvi, SI, Culliford, L, Angelini, GD Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery.. Circulation. (2007). 116 2544–52 [Article] [PubMed]
Christensen, MC, Dziewior, F, Kempel, A, von Heymann, C Increased chest tube drainage is independently associated with adverse outcome after cardiac surgery.. J Cardiothorac Vasc Anesth. (2012). 26 46–51 [Article] [PubMed]